UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012209
Receipt number R000014194
Scientific Title Assessment of medical treatment of diabetes on comorbid diastolic let-ventricular dysfunction observed by cardiac MRI in diabetic patients
Date of disclosure of the study information 2013/11/04
Last modified on 2014/06/25 14:23:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Assessment of medical treatment of diabetes on comorbid diastolic let-ventricular dysfunction observed by cardiac MRI in diabetic patients

Acronym

DMDHF-CMR

Scientific Title

Assessment of medical treatment of diabetes on comorbid diastolic let-ventricular dysfunction observed by cardiac MRI in diabetic patients

Scientific Title:Acronym

DMDHF-CMR

Region

Japan


Condition

Condition

Heart failure with diastolic dysfunction and comorbid diabetes.

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To elucidate the impact of therapeutic intervention for diabetes on diastolic left-ventricular dysfunction.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II,III


Assessment

Primary outcomes

Changes in LV early filling by use of CMR.

Key secondary outcomes

MACE
incidence of hospitalization by heart failure Changes in E/e'
Changes in NT-proBNP
Changes in endothelial function
Changes in circulating DPP4 activity and biomarkers



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral administration of DPP4 inhibitor sitagliptin for 1 year

Interventions/Control_2

Oral administration of anti-diabetic drugs except for DPP4 inhibitor sitagliptin for 1 year

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

70 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

70y/o or older
male and female
T2DM
diastolic dysfunction positive
NYHAI-II
No previous Hx of hospitalization due to heart failure
No hypertension (SBP less than 150 and DBP less than 90)
Approved informed consent

Key exclusion criteria

MACE within 3 months
LVEF<50%
Comorbid atrial fibrillation
MR at more than moderate grade
Patients taking DPP4i or GLP-1 analog
ESRD or HD patient
T1DM
Malignancy within 5 years
Uncontrolled arrhythmia
Encontralled hypertension
Expecting hospitalization within 6 months
Insulin treatment
Indication of cardiac surgery
liver injury
Autoimmune disease
Pulmonary fibrosis
Unstable AP or coronary spastic angina
ASO (>Fontaine grade II)
Contraindication for MRI
Drug allergy to sitagliptin and any antidiabetic drug.




Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuko K. Bando

Organization

Nagoya University

Division name

Cardiology

Zip code


Address

65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan

TEL

052-744-2147

Email

ybando@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yasuko K. Bando

Organization

Nagoya University

Division name

Cardiology

Zip code


Address

65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, Japan

TEL

052-744-2147

Homepage URL


Email

ybando@med.nagoya-u.ac.jp


Sponsor or person

Institute

Cardiology, Nagoya University

Institute

Department

Personal name



Funding Source

Organization

Nagoya University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Mitsubishi-Nagoya hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

名古屋大学医学部附属病院
三菱名古屋病院


Other administrative information

Date of disclosure of the study information

2013 Year 11 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2013 Year 01 Month 04 Day

Date of IRB


Anticipated trial start date

2013 Year 09 Month 13 Day

Last follow-up date

2016 Year 09 Month 30 Day

Date of closure to data entry

2016 Year 09 Month 30 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 11 Month 04 Day

Last modified on

2014 Year 06 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014194


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name